High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with Immune checkpoint inhibitors
High ADA levels were associated with shorter OS and PFS in patients after three cycles of camrelizumab therapy. Furthermore, patients had higher ADA levels after the early phase of treatment, specifically in the first three cycles with camrelizumab. It found that the higher the ADA concentration, the lower the serum camrelizumab concentration.
Authors
- Guobin Fu (ORCID: https://orcid.org/0000-0003-0893-7714)
- Yahui Wang (ORCID: https://orcid.org/0000-0002-7564-8421)
- Jingliang Wang (ORCID: https://orcid.org/0000-0002-4565-5305)
- Weihao Wang (ORCID: https://orcid.org/0000-0002-5896-2793)
- Rui Zhao (ORCID: https://orcid.org/0009-0009-3031-8435)
- Liying Pan
- Fang Luan
- Pancen Ran
Institutions
- Academy of Medical Sciences (GB)
- Shandong University of Traditional Chinese Medicine (CN)
- Shandong University (CN)
- Shandong Provincial Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Immunotherapy Advances
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1093/immadv/ltaf019
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Natural Science Foundation of China